Skip to main content

01-12-2016 | Nausea and vomiting | Book chapter | Article

5. The Role of Neurokinin-1 Receptor Antagonists in CINV

Author: Dip. in Med., M. Med. Bernardo Leon Rapoport

Publisher: Springer International Publishing


Significant advances have been made in controlling chemotherapy-induced nausea and vomiting (CINV) in the past two decades. These advances are primarily due to a greater understanding of the physiological and molecular pathways underlying CINV, which resulted in major progress in the management of patients with CINV. In the early 1990s, CINV treatment included dexamethasone [1]. Improvements in the management of CINV control were achieved with the discovery of 5-hydroxytryptamine (5HT3) receptor and the development of 5HT3 receptor antagonists (RA). Additional improvements in CINV control were further made, with the usage of the combination of 5HT3 RA with dexamethasone or other corticosteroid agents at equivalent doses [2, 3].

Please log in to get access to this content

Related topics